



25 May 2023
EMA/137143/2023

Shortage of Ixiaro (Japanese encephalitis vaccine (inactivated, adsorbed)) suspension for injection	
Indication	Ixiaro is a vaccine that helps protect adults and children aged 2 months and older, against Japanese encephalitis, a disease that causes inflammation of the brain.
Reason for shortage	<p>During the COVID-19 pandemic, demand for Ixiaro was low due to travel restrictions and the company holding the marketing authorisation stopped marketing the product in some EU Member States for commercial reasons. A recent surge in travel has led to an increase in demand and a resulting shortage of Ixiaro in a few EU/EEA countries.</p> <p>This information is based on input from the SPOC working party¹. Further information is available from the relevant national competent authorities.</p>
Member States affected²	Based on information from the SPOC working party the following EU Member States are affected: Italy, Portugal, Romania and Spain.
Monitoring of shortage	<p>EMA's SPOC working party is closely monitoring the supply situation and engaging with the marketing authorisation holder to mitigate the impact of the supply shortage.</p> <p>Summaries of the SPOC working party meetings can found on EMA's website.</p>
Information for healthcare professionals	<ul style="list-style-type: none">• The company holding the marketing authorisation for Ixiaro, Valneva Austria GmbH, stopped marketing the product in some EU Member States.• EMA, in collaboration with the European Medicines Regulatory Network, is monitoring the supply situation closely and taking action as necessary to improve the situation.

¹ The [Medicines Shortages Single Point of Contact \(SPOC\) Working Party](#) is responsible for monitoring and reporting events that could affect the supply of medicines in the EU.

² This information may change. For up-to-date information about the status of a medicine shortage in a particular Member State, contact the national competent authority.



Shortage of Ixiaro (Japanese encephalitis vaccine (inactivated, adsorbed)) suspension for injection

	<ul style="list-style-type: none">• To alleviate the supply situation, affected Member States will receive some of the product intended for other EU Member States where the product is still marketed.• Please consult your country's national shortage register for further advice, including advice on the availability of Ixiaro in your country.
Information for public	<ul style="list-style-type: none">• The company holding the marketing authorisation for Ixiaro stopped marketing the product in some EU Member States. EMA is monitoring the supply situation closely and taking action as necessary to improve the situation.• To alleviate the supply situation, affected Member States will receive some of the product intended for other EU Member States where the product is still marketed.• Please consult your doctor or pharmacist for any questions and for advice on current availability of Ixiaro.• Alternatively you can also consult your country's national shortage register for further information.
Status	Ongoing